started · updated
Precigenetics' Live-Cell Platform Promises Faster Cancer Drug Discovery
Precigenetics, a San Francisco‑based biotech founded by Indian‑origin entrepreneur Parmita Mishra, has developed a live‑cell platform that continuously monitors living cells without dyes, labels or destructive preparation. The technology combines advanced Raman spectroscopy, photonics, microfluidics and computational biology to generate real‑time biochemical information, which the company describes as “live‑cell cinema.”
Experts say the approach could replace traditional static “cell autopsies,” allowing researchers to observe how cancer cells evolve, adapt and respond to candidate drugs. Dr Shyam Aggarwal of Sir Ganga Ram Hospital noted that real‑time observation may help detect subtle biochemical changes and accelerate identification of promising therapies. With India reporting an estimated 1.4 million new cancer cases in 2022 and a projected rise in burden, the platform is positioned to impact cancer research, precision medicine and broader fields such as immunology and neuroscience.